Toggle Main Menu Toggle Search

Open Access padlockePrints

Derivation and validation of the NAFLD Cirrhosis Score (NCS) to distinguish bridging fibrosis from cirrhosis

Lookup NU author(s): Professor Quentin AnsteeORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2022. Separation of bridging fibrosis from cirrhosis in non-alcoholic fatty liver disease (NAFLD) is critical to guide management. Therefore, it was the aim of this study to develop an easy-to-perform score distinguishing F3 and F4 fibrosis in NAFLD. A derivation cohort comprising 251 NAFLD patients with F3 or F4 was used to develop the NAFLD Cirrhosis Score (NCS). The NCS was validated in three independent cohorts with liver histology comprising 1666 participants from the STELLAR trials, 47 patients from China and 2058 patients from the European NAFLD Registry. A model including INR, gGT, ALT, platelets and age discriminated best between patients with bridging fibrosis and cirrhosis with an area under the curve (AUC) of 0.733 (95%CI 0.671–0.795). The diagnostic performance of the NCS was similar in the STELLAR studies (AUC 0.700; 95%CI 0.680–0.730) and a smaller cohort from China (AUC 0.727; 95%CI 0.533–0.921). In the European NAFLD Registry, spanning all histological fibrosis stages, the NCS exhibited an AUC of 0.798 (95%CI 0.766–0.830) to detect cirrhosis. We derived two NCS cut-off values (<64.5 and >79.17) to classify patients at low, intermediate, or high risk for the presence of cirrhosis. Using these cut-offs, further diagnostic workup could be avoided by ruling in or ruling out cirrhosis in approximately half of the patients. Furthermore, NCS identified patients at risk for progression to cirrhosis in the F3 cohort and liver-related outcomes in the F4 cohort. Conclusion: The NCS is a simple tool to improve the identification of compensated cirrhosis within the large group of advanced disease stage and provides prognostic information. Overall, the differentiation of F3 from F4 disease using standard laboratory remains difficult and does not exceed moderate accuracy.


Publication metadata

Author(s): Labenz C, Toenges G, Zheng M-H, Ding D, Myers RP, Galle PR, Armandi A, Ampuero J, Gomez MR, Bugianesi E, Anstee QM, Schattenberg JM

Publication type: Article

Publication status: Published

Journal: European Journal of Internal Medicine

Year: 2022

Online publication date: 17/01/2022

Acceptance date: 08/12/2021

ISSN (print): 0953-6205

ISSN (electronic): 1879-0828

Publisher: Elsevier B.V.

URL: https://doi.org/10.1016/j.ejim.2021.12.011

DOI: 10.1016/j.ejim.2021.12.011


Altmetrics

Altmetrics provided by Altmetric


Share